How the FDA Controls Tobacco

Last updated 6 days ago. Our resources are updated regularly but please keep in mind that links, programs, policies, and contact information do change.

On June 22, 2009, everything changed for tobacco in America. President Barack Obama signed the Family Smoking Prevention and Tobacco Control Act, giving the FDA comprehensive authority to regulate the manufacturing, marketing, and sale of tobacco products for the first time in history.

This was a direct response to decades of legal battles and a Supreme Court decision that had left tobacco products in a regulatory vacuum. For the first time, the nation’s primary public health agency would oversee the leading cause of preventable death and disease in America.

Tobacco use kills over 480,000 Americans annually and costs the economy hundreds of billions in healthcare expenses and lost productivity. Yet tobacco products remain legal, widely available, and heavily marketed.

The FDA’s approach to tobacco regulation is unlike anything else in the agency’s portfolio. These products can’t be made “safe and effective” like drugs—they’re inherently harmful. Instead, the agency operates under a unique “public health” standard that tries to minimize harm at the population level while preserving adult access to legal products.

The Legal Foundation: How Congress Changed the Game

From Supreme Court Defeat to Legislative Victory

The FDA’s tobacco authority didn’t come easily. In 1996, the agency first tried to regulate tobacco products, arguing they were drug delivery devices under existing law. The Supreme Court disagreed in 2000, ruling that Congress hadn’t explicitly granted the FDA such power.

The Tobacco Control Act was Congress’s definitive answer to that ruling. It created a new chapter—Chapter IX—within the Federal Food, Drug, and Cosmetic Act dedicated solely to tobacco products, establishing permanent regulatory architecture with unique standards and carefully negotiated limitations.

The law garnered unusual bipartisan support from traditional public health advocates like the American Cancer Society and the nation’s largest cigarette manufacturer, Philip Morris—signaling a carefully balanced final text that neither completely satisfied nor completely alienated major stakeholders.

The “Public Health Standard”: A Different Approach

Unlike drugs evaluated on “safe and effective” standards, the Tobacco Control Act established a different benchmark: “appropriate for the protection of the public health” (APPH). This standard implicitly acknowledges that no tobacco product is truly safe and that regulation aims to minimize population-level harm.

To meet this standard, the FDA must consider risks and benefits of any regulatory action on the entire population—both current users and non-users. This comprehensive assessment analyzes:

• Whether new products increase or decrease the likelihood that existing tobacco users will quit
• Whether new products increase or decrease the likelihood that non-users, particularly youth, will start using tobacco

This population-level approach means the FDA must weigh, for example, a product’s potential benefit in helping adult smokers transition from cigarettes against its risk of attracting new young users through appealing flavors or marketing.

Powers and Limits: A Political Compromise

The law equipped the FDA with robust regulatory tools while including specific prohibitions that were essential for political passage.

Key Powers Granted:

• Set product standards limiting harmful ingredients or regulating nicotine levels
• Restrict marketing and advertising, especially to youth
• Require premarket review of any new tobacco product
• Mandate new health warnings, including graphic images
• Conduct manufacturing facility inspections every two years
• Assess user fees on manufacturers to fund oversight

Explicit Limitations:

To address industry fears and ensure continued adult access, the FDA is explicitly prohibited from:

• Banning entire classes of tobacco products (all cigarettes, smokeless tobacco, cigars, or pipe tobacco)
• Requiring nicotine reduction to zero in any tobacco product
• Requiring prescriptions to purchase tobacco products
• Banning face-to-face sales in specific retail outlet categories

These limitations were essential political trade-offs enabling passage after decades of failed federal regulation attempts. They created a framework where the FDA could significantly reduce tobacco harm but couldn’t eliminate the industry entirely.

What Products Does the FDA Regulate?

The Original Four (2009)

When the Tobacco Control Act took effect, the FDA immediately gained authority over:

• Cigarettes
• Cigarette tobacco
• Roll-your-own tobacco
• Smokeless tobacco (snuff, chewing tobacco)

The 2016 Expansion: Bringing New Products Under Control

The law gave the FDA power to “deem” other products meeting the tobacco product definition subject to its authority. The agency exercised this power with the Deeming Rule finalized May 5, 2016, representing a massive expansion that brought new products under federal control.

Products deemed in 2016 include:

• Electronic nicotine delivery systems (e-cigarettes, vapes, vape pens, e-liquids)
• All cigars (large cigars, cigarillos, little filtered cigars)
• Hookah (waterpipe) tobacco
• Pipe tobacco
• Novel products like nicotine gels and dissolvable tobacco

Closing the Synthetic Nicotine Loophole (2022)

Following the Deeming Rule, manufacturers began marketing products containing lab-created nicotine rather than tobacco-derived nicotine, arguing these “synthetic nicotine” products weren’t tobacco products and thus outside FDA jurisdiction.

Congress acted again in 2022, amending the law to clarify that tobacco products include those containing nicotine from any source. This closed the loophole and ensured synthetic nicotine products popular among youth faced the same regulations as tobacco-derived products.

This sequence—from initial law to Deeming Rule to synthetic nicotine clarification—illustrates a recurring pattern: regulation is implemented, industry innovates to find gaps, and regulators must act to close them.

The Gateway to Market: Premarket Review

One of the FDA’s most powerful tools is authority to scientifically review all new tobacco products before they can be legally sold. This premarket review serves as a critical gatekeeper preventing introduction of products that are more harmful, addictive, or appealing to youth.

The Grandfather Date: February 15, 2007

Products commercially marketed in the U.S. on or before February 15, 2007, are “grandfathered” and don’t need premarket review to remain available.

Any product not on the market by that date, or any pre-existing product modified in any way (ingredients, design, additives), is a “new tobacco product” requiring FDA marketing authorization before sale.

For products brought under FDA authority by the 2016 Deeming Rule, the deadline to submit marketing applications was September 9, 2020.

Three Pathways to Market

The law outlines three distinct pathways for manufacturers seeking marketing authorization:

Premarket Tobacco Product Application (PMTA): The most comprehensive pathway for truly novel products like e-cigarettes. Applicants must submit extensive scientific evidence demonstrating that permitting marketing would be “appropriate for the protection of the public health,” including detailed data on ingredients, manufacturing processes, health risks, and likely impact on users and non-users.

Substantial Equivalence (SE) Report: Allows marketing by demonstrating a new product is “substantially equivalent” to a specific, legally marketed “predicate product” (one on the market as of February 15, 2007). New products must have the same characteristics as predicate products, or different characteristics that don’t raise different public health questions.

Exemption from Substantial Equivalence (EX REQ): For minor modifications to existing products. Manufacturers can request exemptions if changes—like adding/deleting tobacco additives or changing ingredient quantities—are minor and don’t require full SE reports for public health protection.

The APPH Standard in Action

Application of the “appropriate for the protection of the public health” standard is the cornerstone of PMTA review. The FDA must conduct complex risk-benefit analysis for the entire U.S. population.

The agency can’t authorize products simply because they might be less harmful to individual users than traditional cigarettes. Instead, it must consider net population health effects, weighing whether product availability will:

• Help current adult smokers quit or completely switch from more dangerous combustible products
• Discourage non-users, especially young people, from starting any tobacco use

This high standard has proven a significant hurdle, particularly for flavored e-cigarette products. The FDA consistently finds that potential benefits for adult smokers aren’t sufficient to overcome profound, well-documented youth initiation and addiction risks.

Marketing Orders: Who Makes the Cut?

The FDA’s application of the public health standard has resulted in clear patterns. By examining which products receive Marketing Granted Orders (MGOs) versus Marketing Denial Orders (MDOs), the public can see regulatory principles in practice.

Products Approved for Sale

The FDA has authorized select new tobacco products, primarily those that are non-flavored or demonstrate clear potential to benefit adult smokers while posing minimal youth risk.

Electronic Nicotine Delivery Systems: The first ENDS MGOs were issued in October 2021 to R.J. Reynolds Vapor Company for Vuse Solo tobacco-flavored e-cigarette devices and cartridges. The FDA determined submitted data showed these products could benefit addicted adult smokers who switch completely or significantly reduce cigarette consumption.

Other tobacco-flavored products from brands like NJOY and Logic have received MGOs. In a landmark June 2024 decision, the FDA authorized four menthol-flavored NJOY products—the first non-tobacco flavored e-cigarettes granted marketing orders. The agency concluded evidence for these specific products showed adult smoker benefits sufficient to outweigh youth risks.

Oral Nicotine Products: In January 2025, the FDA authorized 20 varieties of ZYN nicotine pouches. The agency’s review found these products contain substantially lower harmful constituent levels than cigarettes and most smokeless tobacco, with evidence showing significant numbers of adult tobacco users completely switched to ZYN pouches. Crucially, the FDA noted that youth nicotine pouch use remained low, contributing to favorable risk-benefit assessment.

Products Barred from Market

In stark contrast to the small number of MGOs, the FDA has issued MDOs for millions of new tobacco products, the vast majority being flavored e-cigarettes.

Primary Denial Reason: The most common reason is manufacturer failure to provide adequate product-specific scientific evidence demonstrating that potential adult smoker benefits outweigh established, significant youth initiation risks. The FDA states that flavored ENDS applications need particularly “robust and reliable evidence,” such as randomized controlled trials or longitudinal cohort studies.

Examples of Denials:

• Thousands of small and large manufacturers for e-liquids in flavors like Strawberry Cheesecake, Cool Mint, and Citrus
• May 2023 denial of myblu Menthol 2.4% e-cigarette for lacking “sufficient evidence” of added adult smoker benefits compared to tobacco-flavored alternatives
• June 2022 initial MDO to JUUL Labs for all products (later stayed and rescinded in June 2024 for further review based on new case law and applicant-provided information)

Regulating Manufacturing and Ingredients

The FDA’s authority extends beyond finished products into manufacturing processes themselves. The Tobacco Control Act provides tools to oversee how products are made, what they contain, and quality controls used in production.

Registration and Inspection

Any entity qualifying as a tobacco product manufacturer—defined broadly to include anyone who makes, modifies, mixes, assembles, processes, or imports tobacco products—must register annually with the FDA.

Registered domestic manufacturing facilities face FDA inspection every two years to verify compliance with applicable laws and regulations.

Ingredient Disclosure Requirements

Manufacturers must provide detailed ingredient listings for each brand and sub-brand, including:

• All ingredients: tobacco, substances, compounds, and additives
• Quantity of each ingredient
• Information on ingredients added to tobacco, paper, filter, or other product parts

Manufacturers must also report levels of harmful and potentially harmful constituents (HPHCs) identified by the FDA. The agency provides detailed guidance and electronic submission portals like the eSubmitter tool and CTP Portal to help companies comply with complex reporting requirements.

Proposed Manufacturing Standards

In March 2023, the FDA issued a proposed rule to establish Tobacco Product Manufacturing Practice (TPMP) requirements, ensuring products are produced consistently to protect public health.

The proposed rule aims to minimize or prevent:

• Contamination with foreign materials like metal, glass, or plastic
• Inconsistencies between product labels and actual contents, such as nicotine concentration in e-liquids

If finalized, TPMP would require manufacturers to implement controls over product design and development, ensure products meet established specifications, prevent contamination, and establish robust systems for tracing components and recalling substandard products.

Marketing and Sales Restrictions: Protecting Youth

A central Tobacco Control Act pillar is granting the FDA authority to impose significant restrictions on tobacco product sale, distribution, and promotion. Many rules are designed specifically to reduce tobacco appeal to youth and ensure marketing messages aren’t misleading.

Youth Protection Measures

Recognizing that nearly all tobacco use begins in youth and young adulthood, the law includes several youth-focused provisions:

Nationwide Age Restriction: Federal minimum age for tobacco sales, raised to 21 for all tobacco products nationwide in December 2019. Retailers must verify age via photographic ID for customers under 27.

Sales and Distribution Bans:

• Sale of cigarettes in packages fewer than 20
• Distribution of free tobacco product samples (narrow exception for smokeless tobacco in qualified adult-only facilities)
• Sale in vending machines unless facilities are exclusively adult-only

Marketing and Promotion Bans:

• Tobacco brand-name sponsorships of sporting, musical, or cultural events
• Distribution of non-tobacco promotional items (t-shirts, hats) bearing tobacco brand names or logos

Cigarette Flavor Ban: Immediate ban on cigarettes containing “characterizing flavors” like fruit, candy, or coffee, with notable exemptions for tobacco and menthol flavors.

Truth in Advertising Requirements

Modified Risk Claims Prohibition: The law prohibits terms like “light,” “mild,” or “low-tar” on labels or advertising unless companies submit comprehensive Modified Risk Tobacco Product (MRTP) applications and receive FDA authorization. MRTP orders require extensive scientific evidence showing products will significantly reduce individual user harm and benefit population health.

Advertising Content and Placement Restrictions: For cigarettes and smokeless tobacco:

• Ban on outdoor advertising within 1,000 feet of schools and playgrounds
• Requirement that most point-of-sale and magazine advertisements be limited to black-and-white text only

These restrictions were crafted to withstand First Amendment challenges by creating extensive factual records demonstrating links between tobacco marketing and youth initiation.

Health Warnings: Making Risks Visible

A cornerstone of FDA authority is power to mandate clear, prominent, accurate health warnings on tobacco product packaging and advertisements. The Tobacco Control Act sought to overhaul decades-old warning systems shown to be stale and ineffective.

Cigarette Warnings: A Contentious History

TCA Requirements: The law mandated nine new textual warning statements (e.g., “WARNING: Cigarettes cause fatal lung disease”) paired with color graphics depicting negative health consequences. These warnings must cover the top 50% of both front and rear package panels and at least 20% of advertisement areas.

Legal Battles and Delays: Implementation has been fraught with legal challenges:

• FDA issued its first final rule with specific images in 2011, struck down in 2012 by the U.S. Court of Appeals for the D.C. Circuit for violating industry First Amendment rights
• After years of agency inaction, public health groups sued to compel new warning development
• FDA issued a new final rule in March 2020 establishing 11 new textual and graphic warnings featuring photorealistic images of health conditions like bladder cancer, cataracts, and stunted fetal growth
• Implementation remains delayed by ongoing industry litigation; in January 2025, a federal judge halted enforcement pending legal challenge resolution

Warnings for Other Products

The FDA has established specific warning requirements for other tobacco product categories:

Shaping the Future: Major Product Standards

Beyond regulating marketing and sales, the Tobacco Control Act gives the FDA one of its most powerful tools: authority to establish tobacco product standards that can change product composition and characteristics, such as reducing or eliminating harmful ingredients or additives.

The Menthol and Flavored Cigar Controversy

The Proposed Rules: In May 2022, the FDA issued two historic proposed product standards:

• Prohibiting menthol as a characterizing flavor in cigarettes
• Prohibiting all characterizing flavors (except tobacco) in all cigars

The Rationale: The FDA concluded that menthol’s cooling and anesthetic properties reduce cigarette smoke harshness, making it easier for young people to start smoking and harder for existing smokers to quit. Similarly, flavors like fruit punch and strawberry in cigars increase appeal, particularly among youth, contributing to higher initiation rates. The agency highlighted that the tobacco industry historically targeted Black communities with menthol cigarette marketing, leading to profound health disparities.

Political Withdrawal: The proposed rules generated immense debate. While supported by major public health organizations, they faced opposition from the tobacco industry and some civil rights and law enforcement groups concerned about potential illicit markets and disproportionate community impact through increased policing. After multiple delays, the Trump administration officially withdrew both proposed rules in January 2025.

The Revolutionary Nicotine Reduction Proposal

The Proposed Rule: In January 2025, the FDA issued a proposed rule to establish maximum nicotine levels in cigarettes and certain other combusted tobacco products. The proposed cap is 0.7 milligrams nicotine per gram of tobacco—a reduction of over 95% from current market levels.

The Rationale: The FDA’s action is grounded in scientific consensus that while thousands of chemicals in smoke cause disease, nicotine causes the addiction keeping people smoking. By breaking the addiction cycle, the FDA projects the rule could prevent millions of young people from becoming regular smokers and prompt millions of current smokers to quit or switch to less harmful alternatives. The agency estimates the rule could avert 4.3 million deaths by century’s end.

Scope: The proposed standard would apply to cigarettes, roll-your-own tobacco, and most cigars and pipe tobacco, but not e-cigarettes, smokeless tobacco, or premium cigars. The rule is currently in public comment period closing September 15, 2025.

Enforcement: Ensuring Compliance

To ensure regulation compliance, the FDA operates a comprehensive program targeting all tobacco supply chain levels, from large manufacturers to local retailers.

Retailer Compliance Program

A major enforcement focus is retailers who prevent youth tobacco access. The Tobacco Retailer Compliance Check Inspection Program is a nationwide effort monitoring federal law adherence.

Undercover Inspections: The program primarily uses unannounced, undercover buy inspections where trained, underage individuals attempt tobacco purchases, checking for minimum age law violations and requirements to verify customer age under 27.

Scale: Since 2010, the FDA and state contractors have conducted over one million inspections, with results publicly available in the Tobacco Compliance Check Outcomes database.

The Enforcement Ladder

When violations are found, the FDA employs escalating enforcement actions:

Warning Letters: For first-time violations, formal letters detail specific violations and require correction plans within 15 working days.

Civil Money Penalties: For repeated violations, the FDA imposes fines on a sliding scale:

No-Tobacco-Sale Orders (NTSOs): For retailers with persistent non-compliance—five or more repeated violations within 36 months—the FDA can prohibit tobacco sales for specified periods.

Seizures and Injunctions: For significant or ongoing violations, the FDA can work with the Department of Justice to seize illegal products and obtain court injunctions halting sales.

Public Education: “The Real Cost” Campaign

Beyond regulation and enforcement, the FDA leads major public education initiatives designed to reduce tobacco demand, especially among youth.

Campaign Overview

Launched in 2014, “The Real Cost” is the FDA’s evidence-based youth tobacco prevention campaign targeting at-risk 12-17 year-olds to prevent initiation and discourage experimentation progression to regular use.

Methods and Messaging

Multi-Channel Approach: Comprehensive media strategy including traditional channels (television, radio) and heavy emphasis on digital platforms where teens spend time (social media, online video streaming, gaming platforms).

Targeted Messaging: Messages developed through extensive research to identify themes resonating with adolescents, focusing on immediate, relatable consequences rather than solely long-term diseases:

• Loss of Control: Framing addiction as immediate independence loss
• Dangerous Chemicals: Using graphic imagery illustrating toxic substances in tobacco smoke and vape aerosol
• Health and Cosmetic Consequences: Dramatizing negative effects concerning youth (tooth loss, skin damage, respiratory issues)

Proven Effectiveness

Independent outcome evaluations show overwhelmingly positive results:

Preventing Initiation: Studies estimated the campaign prevented up to 587,000 youth from smoking initiation in its first few years. A 2025 study found the e-cigarette prevention campaign prevented an estimated 444,252 U.S. youth from starting e-cigarette use between 2023-2024.

Cost-Effectiveness: The cigarette prevention component saves an estimated $180 in future healthcare costs and lost productivity for every $1 spent on the campaign.

The Regulatory Landscape Today

The FDA’s tobacco regulation represents one of the most complex and politically charged areas of federal oversight. Unlike traditional FDA-regulated products that can be made safe and effective, tobacco products are inherently harmful yet legal for adult use.

The agency operates under constant tension between protecting public health—especially preventing youth addiction—and respecting adult consumer choice in a legal market. This balance plays out in every major decision, from which products receive marketing authorization to how health warnings are designed.

Recent developments highlight this ongoing evolution. The withdrawal of menthol cigarette and flavored cigar bans shows how political winds can shift regulatory priorities, while the proposed nicotine reduction rule demonstrates the FDA’s continued pursuit of transformative public health interventions.

The premarket review process has become the primary battleground for determining which new products reach consumers. The FDA’s high evidentiary bar for flavored products has effectively removed most flavored e-cigarettes from legal markets, though enforcement challenges and legal appeals continue.

Meanwhile, the rise of novel products like nicotine pouches and synthetic nicotine products shows how industry innovation constantly tests regulatory boundaries, requiring ongoing legislative and regulatory adaptation.

What This Means for Consumers

For current tobacco users, FDA regulation aims to ensure products meet quality standards, provide accurate health information, and offer potential pathways to less harmful alternatives. The agency’s focus on preventing youth access may limit product variety but serves the broader public health goal of reducing tobacco initiation.

For parents and communities, FDA tobacco regulation provides federal support for preventing youth tobacco use through age restrictions, marketing limitations, and public education campaigns. However, the regulatory system’s complexity means that staying informed about which products are legal and how they’re regulated requires ongoing attention.

For public health advocates, the FDA’s tobacco authority represents unprecedented opportunity to address the nation’s leading cause of preventable death. Yet the political constraints and industry legal challenges show that meaningful change often requires sustained effort across multiple administrations and legislative sessions.

The future of tobacco regulation will likely continue evolving as new products emerge, scientific understanding advances, and political priorities shift. What remains constant is the fundamental tension between harm reduction for current users and prevention of future initiation—a balance that defines every aspect of how America regulates its deadliest legal products.

Understanding this regulatory framework empowers citizens to engage more effectively in tobacco control policy discussions, make informed choices about tobacco use, and support evidence-based approaches to reducing tobacco’s devastating public health impact.

Our articles make government information more accessible. Please consult a qualified professional for financial, legal, or health advice specific to your circumstances.